search
Back to results

Cervical Plexus Hydrodissection With D5W for PTSD

Primary Purpose

PTSD

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
BCPHD with D5W
Waiting period with usual care
Sponsored by
Dr. Dean Reeves Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PTSD focused on measuring Dextrose, Hydrodissection, Cervical Plexus

Eligibility Criteria

19 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • U.S. veteran or first responder
  • Score of 31 or more on the PCL-5 (Post traumatic stress disorder checklist)
  • Not involved in another study of PTSD treatment
  • Not planning to move out of the Kansas City area for 18 months or more
  • Availability on Monday evenings
  • Reliable transportation
  • Within a 60 minute drive of Roeland Park, Kansas
  • Willing to provide 2 email and 2 phone contact methods
  • Willing to answer 20 minutes of questions multiple times over the course of a year
  • Comfortable with computers
  • Willing to be assigned to a control group for 8 weeks
  • CAPS-5 Rating of greater than or equal to 26

Exclusion Criteria: None separate from inclusion criteria

Sites / Locations

  • Entheomed ClinicRecruiting
  • Bowler Medical ClinicRecruiting
  • Stanley H.K. Lam ClinicRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

BCPHD-D5W with usual care

Waiting period with usual care

Arm Description

Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, and 8 weeks. All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.

All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.

Outcomes

Primary Outcome Measures

PCL-C Score
Measurement of response to very stressful experiences in the last month. Range from 0 to 80. An improvement is a reduction in the PCL-5 score.
Hospital Anxiety and Depression scale
Measurement of symptoms of anxiety and depression. Range from 0 to 21. An improvement is a reduction in the HADS score.

Secondary Outcome Measures

Satisfaction with treatment outcome as measured by a 0-10 Numerical Rating Scale (NRS)
Anchors include "0 = no satisfaction" and "10 = complete satisfaction"
EuroQOL-5D-5L + C scale
Measurement of general quality of life. Each question has a range from 1 to 5. An improvement is a reduction in score.

Full Information

First Posted
June 4, 2020
Last Updated
September 11, 2023
Sponsor
Dr. Dean Reeves Clinic
Collaborators
Francois Louw, M.D, Jannice Bowler, M.D., Stanley Lam, M.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT04421573
Brief Title
Cervical Plexus Hydrodissection With D5W for PTSD
Official Title
Cervical Plexus Hydrodissection With D5W for PTSD Versus Delayed Treatment/Usual Care
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 10, 2023 (Actual)
Primary Completion Date
October 1, 2026 (Anticipated)
Study Completion Date
October 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dr. Dean Reeves Clinic
Collaborators
Francois Louw, M.D, Jannice Bowler, M.D., Stanley Lam, M.D.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and observational results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomized trial will compare dextrose injection with a delayed/usual treatment control.
Detailed Description
PTSD is a well-recognized debilitating mental health condition associated with previous trauma exposure. It is part of the DSM-5 Trauma and Stressor related disorders category. Treatments for PTSD normally involve a multi-disciplinary approach. First-line treatments include psychotherapy and serotonergic reuptake inhibitors. Many patients fail pharmacotherapy and psychotherapy. Unilateral stellate ganglion block performed favorably for treatment of PTSD in a recent RCT, based upon an expectation that the cervical sympathetic system is neuropathically upregulated in PTSD. However, inclusion of lidocaine requires the presence of an emergency response team due to the potential for inadvertent intravascular injection with generalized seizures or hypotension, and inadvertent laryngeal or phrenic nerve block. Perineural injection of peripheral nerves, plexi, or sympathetic ganglia with dextrose 5% in water (D5W), has performed well empirically in the treatment of post-traumatic stress disorder. No lidocaine is utilized, which allows for avoidance of lidocaine toxicity risk, or any risk of nerve block. Because of that, bilateral procedures are feasible, and these procedures can be performed in any outpatient office with ultrasound availability, as emergency team backup is not necessary, making the procedure readily accessible. A cumulative benefit has been observed, as well. The effects of BHDCP with D5W as a stand-alone treatment for PTSD has not been formally evaluated. The primary objective of this study is to determine the short term effects of BHDCP with D5W on anxiety and longer-term effects on the Post Traumatic Stress Disorder Check List for Civilians (PCL-C), The primary hypotheses are that BHDCP with D5W will outperform a waiting/usual care group in both anxiety reduction and PCL-5 score improvement. A study size of 24 is planned, based on power analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PTSD
Keywords
Dextrose, Hydrodissection, Cervical Plexus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized open-label crossover study comparing BHDCP with D5W versus a waiting period in which usual care is allowed.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BCPHD-D5W with usual care
Arm Type
Experimental
Arm Description
Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, and 8 weeks. All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
Arm Title
Waiting period with usual care
Arm Type
Active Comparator
Arm Description
All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
Intervention Type
Procedure
Intervention Name(s)
BCPHD with D5W
Intervention Description
D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
Intervention Type
Procedure
Intervention Name(s)
Waiting period with usual care
Intervention Description
Same as previous group description
Primary Outcome Measure Information:
Title
PCL-C Score
Description
Measurement of response to very stressful experiences in the last month. Range from 0 to 80. An improvement is a reduction in the PCL-5 score.
Time Frame
3 months
Title
Hospital Anxiety and Depression scale
Description
Measurement of symptoms of anxiety and depression. Range from 0 to 21. An improvement is a reduction in the HADS score.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Satisfaction with treatment outcome as measured by a 0-10 Numerical Rating Scale (NRS)
Description
Anchors include "0 = no satisfaction" and "10 = complete satisfaction"
Time Frame
3 months
Title
EuroQOL-5D-5L + C scale
Description
Measurement of general quality of life. Each question has a range from 1 to 5. An improvement is a reduction in score.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Not involved in another study of PTSD treatment Reliable transportation Comfortable with computers Tried 2 or more medications for treatment of PTSD symptoms Tried 2 or more non-medication treatments for PTSD symptom No known life-threatening illness Not taking daily narcotics Not having 3or more alcoholic drinks on an average day No active suicidal plans No major surgery plans No major life stress that might interfere with completing study Symptoms for more than 1 year Not planning to move for next 18 months. Living within an hour of Kelowna or Victoria, British Columbia, or Hong Kong Wiling to provide 2 email and 2 phone contact methods Willing to answer questions on multiple occasions over the course of a year. Willing to be assigned to 3 months of usual care treatment No diagnosis of schizophrenia, Borderline Personality Disorder, or Bipolar Disorder. No severe needle phobia Chronic pain ≤ 5/10 PCL-C score ≥ 50 Exclusion Criteria: None separate from inclusion criteria
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kenneth D Reeves, M.D.
Phone
9133621600
Email
DeanReevesMD@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Clare R Solso, R.N.
Phone
4058197777
Email
cereeves2002@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenneth D Reeves, M.D.
Organizational Affiliation
Dr. Dean Reeves Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Entheomed Clinic
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1Y6T8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francois Louw, M.D.
Phone
2364206854
Email
doclouw@mail.ubc.ca
First Name & Middle Initial & Last Name & Degree
Nina Gregoire
Email
nina44@student.ubc.ca
Facility Name
Bowler Medical Clinic
City
Victoria
State/Province
British Columbia
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jannice Bowler, MB:ChB
Phone
7884060077
Email
jannicebowler@icloud.com
First Name & Middle Initial & Last Name & Degree
Nina Gregoire
Email
nina44@student.ubc.ca
Facility Name
Stanley H.K. Lam Clinic
City
Hong Kong
State/Province
Hong Kong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stanley Lam, M.D.
Email
DrLamKH@gmail.com
First Name & Middle Initial & Last Name & Degree
Nina Gregoire
Email
nina44@student.ubc.ca

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31693083
Citation
Rae Olmsted KL, Bartoszek M, Mulvaney S, McLean B, Turabi A, Young R, Kim E, Vandermaas-Peeler R, Morgan JK, Constantinescu O, Kane S, Nguyen C, Hirsch S, Munoz B, Wallace D, Croxford J, Lynch JH, White R, Walters BB. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Feb 1;77(2):130-138. doi: 10.1001/jamapsychiatry.2019.3474. Erratum In: JAMA Psychiatry. 2020 Jan 2;: JAMA Psychiatry. 2020 Sep 1;77(9):982.
Results Reference
result

Learn more about this trial

Cervical Plexus Hydrodissection With D5W for PTSD

We'll reach out to this number within 24 hrs